By Michael Kim
NASDAQ:HCTI
READ THE FULL HCTI RESEARCH REPORT
Ahead of 4Q25/full-year 2025 results likely to be announced later this month, we highlight several key strategic/financial announcements during the quarter, including:
1. Strategic M&A: Following the initial announcement of a Letter of Intent (LOI) in October 2025, the company recently disclosed the signing of a definitive agreement to acquire certain assets from Teyame AI LLC, a leading provider of AI-powered Customer Experience (CX) solutions based in Spain. More specifically, Teyame offers call center/telemarketing, KPI reporting/data analytics, and marketing strategy services, along with omnichannel CX platforms leveraging Agentic AI, or autonomous systems incorporating Large Language Models (LLMs) that independently plan/execute multi-step workflows. Stepping back, Teyame will likely transition into a separate subsidiary of Healthcare Triangle (NASDAQ:HCTI), with management focused on cross-selling Teyame’s CX solutions to enhance patient engagement, as well as leveraging Teyame’s presence in Spain to increasingly penetrate the LatAm and European markets. Terms of the transaction include a total consideration of up to $50 million consisting of upfront cash payments and shares of HCTI common stock and convertible preferred stock, as well as an equity-based contingent earnout payment. From a financial perspective, the transaction is likely to be highly accretive given that the acquired assets generated ~$32 million in revenue and ~$3.6 million in EBITDA in fiscal 2025.
2. Capital reload: From a financing perspective, management recently announced a series of capital raises to fund the Teyame acquisition and provide working capital. More specifically, HCTI raised $4.0 million via the sale of 681,553 shares of common stock at $5.81 per share under the company’s $20 million At-the-Market (ATM) offering program. Separately, the company issued $15 million of senior unsecured convertible notes, with an option to issue an incremental $15 million of notes subject to investor approvals. The first tranche of $7.5 million of notes closed in November 2025, with the second tranche issuable subsequent to an effective registration statement for the resale of related shares.
3. Increasingly leveraging QuantumNexis: From an organic growth standpoint, senior officials remain focused on leveraging QuantumNexis, the company’s subsidiary providing digital mental health solutions and AI-powered Hospital Information Systems across Asia, the Middle East, Africa, and Europe. More recent initiatives include: a) the launch of operations in Dubai to target high-growth markets in Gulf Cooperation Council (GCC) countries; b) a joint venture with Golden Code Holdings in Saudi Arabia to capitalize on Saudi Vision 2030, the Kingdom’s digital healthcare transformation strategy; c) a strategic partnership with TNG Digital, a payments and financial services platform in Malaysia, to market QuantumNexis’s digital mental health solutions; and d) a development partnership with Better.care, a digital healthcare platform provider, to capture incremental growth opportunities across Europe, the Middle East, and Africa.
4. Share repurchases: Following the recent 1:60 reverse stock split to regain compliance with Nasdaq listing requirements (bringing the number of shares of common stock outstanding to 757K as of February 10, 2026), the Board announced a $2 million share repurchase authorization. While the timing and level of potential share repurchases remain at management’s discretion, we note the current authorization represents a considerable percentage of the stock’s current market capitalization.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.